The DNA Damage Response and Tumorigenesis in the Brain

大脑中的 DNA 损伤反应和肿瘤发生

基本信息

批准号：
9277198
负责人：
PETER J MCKINNON
金额：
$ 43.03万
依托单位：
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-04-01 至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9277198
关键词：
Address B-Cell Lymphomas Base Excision Repairs Bioinformatics Biology Brain Brain Neoplasms Cancer Etiology Cell Proliferation Childhood Childhood Brain Neoplasm Childhood Central Nervous System Neoplasm Chromatin Chromatin Structure Chromosome Fragile Sites Critical Pathways DNA DNA Damage DNA Repair DNA Repair Pathway DNA Sequence Alteration DNA strand break Defect Development Disease Epigenetic Process Event Gene Cluster Gene Expression Genome Genome Stability Genomic Instability Glioblastoma Glioma Gliomagenesis Heterogeneity Histology Histone H3 Histones Histopathology Human Hypersensitivity Individual Laboratories Lesion Link Maintenance Malignant Childhood Neoplasm Malignant Neoplasms Modeling Molecular Molecular Profiling Mus Mutation Neoplasms Nervous system structure Nonhomologous DNA End Joining PDGFRA gene Pathogenesis Pathway interactions Patients Population Predisposition Proteins Proto-Oncogenes Research Series Signal Transduction Solid Stress Survival Rate TP53 gene Topoisomerase Treatment Efficacy Tumor Biology Tumor Suppression base cell type childhood cancer mortality comparative experimental study genetic signature genome integrity homologous recombination human disease improved in vivo member mouse model mutant nerve stem cell neurodevelopment neurogenesis new therapeutic target novel outcome forecast prevent progenitor programs relating to nervous system repaired response spatiotemporal stem targeted treatment telomere tumor tumor heterogeneity tumorigenesis

项目摘要

Summary - Project 2 Brain tumors are the most common solid malignancies of childhood and are a leading cause of cancer-related death in children. 15-20% of pediatric CNS tumors are high-grade gliomas (HGG), and individuals with these tumors have a 2-year survival rate of 10-30%. Despite extensive research into the molecular basis of gliomagenesis, current therapies remain ineffective, and the majority of patients die from their disease. More effective therapeutic strategies are likely to come from a detailed understanding of glioma pathogenesis. We have developed a unique series of new HGG mouse models, relevant to the human disease, which are characterized by a range of histopathology reflective of the specific defect in the DNA damage response. In Aim 1 of this proposal we will determine the genomic alterations and gene expression profiles that underpin these gliomas, particularly in the context of human disease and other mouse glioma models, either established or under development in other projects in this program. We will also determine the basis for tumor heterogeneity in these models by ascertaining the detailed developmental origins of these gliomas and the relative susceptibility of different neural progenitors to transformation. These analyses will illuminate critical aspects of the pathogenesis of gliomas for which there is a paucity of definitive information. Finally, we will also determine cooperativity in these models with other mutations found in human pediatric HGG, including histone H3 mutations, taking advantage of novel models generated by other projects within the program. In Aim 2 we propose experiments to establish which DNA repair pathways are critical for genome stability at different cortical progenitor stages and how this is linked to chromatin. Because histone mutations and other epigenetic alterations have recently been identified as causative molecular changes in pediatric HGG, our study will be of central importance for understanding connections between DNA damage signaling, epigenetics and tumorigenesis. In Aim 3 we will determine if DNA breaks associated with early replicating fragile sites account for DNA structural alterations central to gliomagenesis. Collectively, findings from this study will provide fundamental new information to delineate glioma biology that will be important for developing targeted therapy for these diseases.

摘要 - 项目2 脑肿瘤是童年最常见的固体恶性肿瘤，是与癌症有关的主要原因儿童死亡。 15-20％的小儿中枢神经系统肿瘤是高级神经胶质瘤（HGG），其中有这些肿瘤的生存率为10-30％。尽管对分子基础进行了广泛的研究神经胶质作用，当前疗法仍然无效，大多数患者死于疾病。更多的有效的治疗策略可能来自对神经胶质瘤发病机理的详细理解。我们已经开发了一系列与人类疾病有关的独特新型HGG小鼠模型以一系列组织病理学的特征反映了DNA损伤反应中的特定缺陷。在该提案的目标1我们将确定基本的基因组改变和基因表达谱。这些神经胶质瘤，特别是在人类疾病和其他小鼠神经胶质瘤模型的背景下建立或该计划的其他项目中的开发。我们还将确定肿瘤的基础这些模型中的异质性通过确定这些神经胶质瘤的详细发育起源和不同神经祖细胞转化的相对敏感性。这些分析将阐明关键神经胶质瘤发病机理的各个方面，其确定性信息很少。最后，我们会的还可以确定这些模型中与人儿科HGG中发现的其他突变的合作性，包括组蛋白H3突变，利用程序中其他项目产生的新型模型。在 AIM 2我们提出实验，以确定哪些DNA修复途径对于基因组稳定性至关重要不同的皮质祖细胞阶段以及如何将其与染色质联系起来。因为组蛋白突变和其他最近已经确定表观遗传学改变是小儿HGG的病原体分子变化，我们研究对于理解DNA损伤信号，表观遗传学之间的联系至关重要和肿瘤发生。在AIM 3中，我们将确定DNA是否与早期复制脆弱位点相关考虑了神经胶质作用中心的DNA结构改变。总的来说，这项研究的发现将为描述神经胶质瘤生物学提供基本的新信息，这对于开发目标很重要这些疾病的治疗。